Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.80 |
| ▸ | MAOB | P27338 | 6/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.80 |
| ▸ | SDHA | P31040 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CALML3 | P27482 | 1/20 | 0.80 |
| ▸ | F10 | P00742 | 7/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498511 | 1.00 | MAOA (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| Hydrochloric Acid SCHEMBL4689047 | 0.99 | MAOA (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| Hydrochloric Acid SCHEMBL4689051 | 0.99 | MAOA (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5818098 | 0.96 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| Phosphonic Acid SCHEMBL5325175 | 0.96 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL5943313 | 0.95 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL6509850 | 0.95 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL5727900 | 0.95 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10151522 | 0.94 | MAOA (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4163701 | 0.93 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117222433-A | Medicaments conjugated to hexose phosphate and methods of making and using the same | 密西西比州立大学 | 2023-12-12 | — | — | CN | claimed |
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | MISSISSIPPI STATE UNIVERSITY (US) | 2023-11-23 | — | — | US | claimed |
| CN-1237056-C | Oxazolidone compound, preparing method and use thereof | SHANGHAI DRUG INST CHINESE ACA (CN) | 2006-01-18 | — | — | CN | claimed |
| EP-4219437-B1 | BAKUCHIOL DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI SHIMEI PHARMACEUTICAL CO LTD (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-11912650-B2 | Bakuchiol derivatives, pharmaceutically acceptable salts thereof, and preparation method and use of the same | JIANGXI SHIMEI PHARMACEUTICAL CO., LTD (CN) | 2024-02-27 | — | — | US | disclosed |
| CN-117222433-A | Medicaments conjugated to hexose phosphate and methods of making and using the same | 密西西比州立大学 | 2023-12-12 | — | — | CN | disclosed |
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | MISSISSIPPI STATE UNIVERSITY (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | MISSISSIPPI STATE UNIVERSITY (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | MISSISSIPPI STATE UNIVERSITY (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4221755-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | Mississippi State University (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4219437-A1 | BAKUCHIOL DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Jiangxi Shimei Pharmaceutical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-0918769-A1 | SUBSTITUTED PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTI-BACTERIAL AGENTS | AstraZeneca AB (SE) | 1999-06-02 | — | — | EP | disclosed |
| EP-0918770-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | AstraZeneca AB (SE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998001446-A1 | SUBSTITUTED PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTI-BACTERIAL AGENTS | ZENECA LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001447-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ZENECA LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| EP-0730591-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5547950-A | FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | THE UPJOHN COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| WO-1995014684-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | THE UPJOHN COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0640077-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023384-A1 | OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | GFPT1, PHPT1, SLC2A1 | MAOA 2364/4885MAOB 3136/4885PTGS1 3999/4885 |
| US-11912650-B2 | Bakuchiol derivatives, pharmaceutically acceptable salts thereof, and preparation method and use of the same | CEL, NPC1L1, LIPA | MAOA 1939/4885MAOB 2396/4885PTGS1 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.